Aditxt (NASDAQ: ADTX), a social innovation platform focused on accelerating promising health innovations, announced it will implement a 1-for-113 reverse stock split of its common stock, effective at the opening of trading on Nov. 3, 2025. The stock will continue trading under the symbol ADTX. The move, approved by stockholders on Sept. 23, 2025, is intended to help the company regain compliance with Nasdaq’s minimum bid price requirement.
Under the reverse split, every 113 shares of issued and outstanding common stock will convert into one share, with fractional shares rounded up. The adjustment is a strategic step to boost the stock price and meet the $1.00 minimum bid price required by Nasdaq for continued listing. Aditxt’s decision underscores the company’s commitment to maintaining its public listing and access to capital markets.
According to the press release, the reverse stock split is part of a broader effort to stabilize the company’s financial position. Aditxt operates a unique model that democratizes innovation, ensuring every stakeholder’s voice is heard and valued. The company currently runs four programs focusing on autoimmunity, cancer and early disease detection, infectious diseases, and women’s health.
Investors can find the latest news and updates regarding ADTX in the company’s newsroom at https://ibn.fm/ADTX. The full press release detailing the reverse stock split is available at https://ibn.fm/KgRGL.
The reverse stock split is a common tactic for companies facing delisting due to low share prices. By reducing the number of shares outstanding, the stock price increases proportionally, which can help meet exchange requirements. However, the move does not change the company’s underlying market capitalization and may not address fundamental operational challenges.
Aditxt’s announcement highlights the importance of compliance with exchange rules for companies listed on Nasdaq. Failure to maintain minimum bid price could lead to delisting, which would negatively impact liquidity and investor confidence. The reverse split is a proactive measure to avoid such outcomes.
This development matters to investors and stakeholders as it reflects Aditxt’s efforts to secure its listing status while continuing to advance its innovation platform. The company’s focus on health innovations, particularly in areas like autoimmunity and cancer detection, remains central to its mission. The reverse split may also influence shareholder value in the short term, as fractional shares are rounded up, potentially benefiting some holders.
